NCT03910361View on ClinicalTrials.gov

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

July 2, 2020

Study Completion Date

July 2, 2020

Conditions
Type2 DiabetesNon-Alcoholic Fatty Liver Disease
Interventions
DRUG

Evogliptin

evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd

DRUG

Pioglitazone

pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd

Trial Locations (7)

Unknown

Samsung Medical Center, Changwon

Soonchunhyang University Hospital, Cheonan

Keimyung Dongsan University Medical Center, Daegu

Hanyang University Guri Hospital, Guri-si

Catholic University of Seoul ST.Mary's Hospital, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT03910361 - Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases | Biotech Hunter | Biotech Hunter